Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is positioned for strong long term growth, as evidenced by its recent financial results where it exceeded sales expectations and has a robust pipeline of clinical programs targeting multiple diseases. Its recently launched product, Papzimeos, has shown strong sales growth potential and the company has filed for an MAA with the EMA, which could vastly increase its addressable market. With favorable IP protection and potential expansion into pediatric patients, Precigen's stock presents as an attractive investment opportunity. However, potential risks include clinical, regulatory, commercial, partnership, financial, and intellectual property, as highlighted by management.

Bears say

Precigen is facing potential headwinds as they work to gain activation from targeted integrated delivery networks (IDNs) and community hospitals to reach key physicians for their AdenoVerse immunotherapy and UltraCAR-T therapies. Despite early promising launch metrics and positive enrollment for their Patient Support Hub, the activation of 93 targeted IDNs and community hospitals remains a rate limiting step for the company. Additionally, while management plans to provide updates on their PRGN-2009 clinical program in 2H26, Precigen's financials could be further strained if their first commercial product, Papzimeos, does not perform as expected.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.